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A recombinant Hc fragment of botulinum neuro- 
toxin, serotype A (rBoNTA(Hc)), has been successfully 
expressed in a Mutt strain of the methylotrophic yeast 
Pichia pastoris for use as an antigen in a proposed 
human vaccine. Fermentation employed glycerol 
batch, glycerol-fed batch, and methanol-fed batch 
phases to achieve high cell density. Induction times 
were short to maximize rBoNTA(Hc) production while 
minimizing proteolytic degradation. Concentration of 
rBoNTA(Hc) in yeast cell lysates was generally 1-2% of 
the total protein based on ELISA analysis. The Hc 
fragment was purified from cell lysates using a multi- 
step ion-exchange (IEC) chromatographic process, in- 
cluding SP, Q, and HS resins. The zwitterionic deter- 
gent Chaps was included in the buffer system to 
combat possible interactions, such as protein-protein 
or protein-DNA interactions. Following IEC was a hy- 
drophobic interaction chromatography (HIC) polish- 
ing step, using phenyl resin. The Hc fragment was 
purified to >95% purity with yields up to 450 mglkg 
cells based on ELISA and Bradford protein assay. The 
purified Hc fragment of serotype A was stable, elicited 
an immune response in mice, and was protected upon 
challenge with native botulinum type A neurotoxin. 
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The bacteria Clostridium botulinum produces seven 
serologically distinct forms (A-G) of botulinum neuro- 
toxin which are similar in structure (1). In humans, 
these neurotoxins cause acute toxicity, which results in 
fatal paralysis of respiratory muscles (2). Food poison- 
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ing is the familiar source of human botulism. However, 
the common occurrence of infant botulism (3) and the 
use of agents such as botulinum toxin in biological 
warfare (4) have heightened the need for safe, inexpen- 
sive, and efficacious vaccine against all seven sero- 
types. If successful, a recombinant subunit vaccine 
could potentially replace the current formalin-inacti- 
vated pentavalent (types A-E) toxoid vaccine as a safer 
alternative. 
Botulinum neurotoxin is processed from a 150-kDa 
precursor to a dimer consisting of light chain (-50 
kDa) and heavy chain (-100 kDa) subunits, connected 
by a single disulfide bridge (5,6). The C-terminal half of 
the heavy chain (the Hc fragment)2 functions in bind- 
ing of the toxin (7-9) to specific receptors on peripheral 
Abbreviations used: AOX1, alcohol oxidase 1; ABTS, 2,2'-azino- 
di-(3-ethylbenzthiazoline-6-sulfonate); BSM, basal salts medium; 
Chaps, (3-[(3-cholamidopropyl)dimethylammonio]-l-propanesulfon- 
ate);  CV, column volumes; DAB, diaminobenzidine; DO, dissolved 
oxygen; DV, diafiltration volumes; EBA, expanded-bed absorption 
chromatography; ED,,, efficacious dose to protect 50% of test ani- 
mals; EDTA, ethylenediaminetetraacetic acid; ELISA, enzyme- 
linked immunosorbent assay; FT, flowthrough fraction; H,, heavy 
chain C-terminal fragment; H,, heavy chain N-terminal fragment; 
HIC, hydrophobic interaction chromatography; HRP, horseradish 
peroxidase; HS, high-density sulfonic acid; i.d., inner diameter; IEC, 
ion-exchange chromatography; IgG, immunoglobulin G; LD,, lethal 
dose to kill 50% of test animals; Mops, 3-(N-morpho1ino)propanesul- 
fonic acid; MW, molecular weight; MWCO, molecular weight cutoff; 
OD, optical density; PBS, phosphate-buffered saline; PBS-TT, phos- 
phate-buffered saline with Tween 20 and thimerosal; PI, isoelectric 
point; PMSF, phenylmethylsulfonyl fluoride; PVDF, polyvinylidene 
difluoride; Q,  quaternary amine; rBoNTA(H,), recombinant botuli- 
num neurotoxin, serotype A, heavy chain C-terminal fragment; RDB, 
regeneration dextrose medium with biotin; SDS-PAGE, sodium do- 
decyl sulfate-polyacrylamide gel electrophoresis; SP,  sulfopropyl; 
TP,  total protein concentration; YNB, yeast nitrogen base medium; 
YPD, yeast extract peptone dextrose medium. 
Tn~s  ancle IS a , S godernmenl \/or< ana s no1 sJbject lo copyr gnt In tne ,nllea Slates 
394 POTTER ET AL 
cholinergic nerve cells (10). The N-terminal half of the 
heavy chain (H,) forms channels in phospholipid mem- 
branes (1 1,12) and facilitates internalization (1 3) of the 
light chain, a zinc-endopeptidase (14,15) which targets 
nerve cells (16). While the complete holotoxin is re- 
quired for biological toxicity, the Hc fragments alone 
are nontoxic and antigenic (17,18) and have demon- 
strated the ability to elicit a protective immune re- 
sponse in animals challenged with native botulinum 
toxin (19-22). Thus, investigations are ongoing to de- 
velop a multivalent vaccine against botulism using the 
Hc fragments of C. botulinum neurotoxin (2 1-26). A 
recombinant C fragment botulinum neurotoxin pro- 
duced in Escherichia coli has been shown to elicit an 
immune response in mice (19). Previously, recombi- 
nant Hc fragment of serotypes B and F have been 
expressed in the methylotrophic yeast Pichia pas- 
toris and purified to homogeneity (21,27). This paper 
similarly describes the successful expression, purifica- 
tion development, and pilot-scale purification of the 
Hc fragment of botulinum neurotoxin serotype A 
(rBoNTA(Hc)) from P. pastoris. 
Methylotrophic yeast can utilize methanol for 
growth and energy (28-30) and P. pastoris has been 
used extensively as a host system for the expression of 
foreign genes (3 1-39). Intracellular expression of a 
synthetic gene coding the Hc fragment of rBoNTA is 
possible by integration into the A O X l  gene of the Mut' 
strain (39 - 43) of P. pastoris. Switching the cell's car- 
bon source from glycerol to methanol activates the 
A O X l  promoter (44-46) and induces production of 
rBoNTA(Hc) in Pichia. A complete discussion of a 
model describing rBoNTA(Hc) production in P. pastoris 
is described elsewhere (47). 
MATERIALS AND METHODS 
Expression vector construction and cell culture. A 
recombinant strain of P. pastoris [GS 1 15-(hid)] was 
transformed with the integrative plasmid PHIL-D4 (a 
gift from the Phillips Petroleum Co., Bartlesville, OK) 
containing a synthetic gene encoding the putative frag- 
ment C region (heavy chain fragment) of botulinum 
toxin type A. Integration was performed with an SstI- 
digested construct that  targets integration by single 
crossover in the chromosomal A O X l  locus of P. pastoris 
such that  the gene remains intact a s  the Mut' pheno- 
type. Transformants were selected for conversion to 
His' selection on RDB medium (48) containing 20 g/L 
agar and then further selected for high copy number by 
their ability to grow on YPD medium (48) containing 
the antibiotic G418. Seed cultures of the selected trans- 
formant, designated as BAC-C-09056-A9 [BoNTA(Hc)/ 
PHIL-D4], were prepared in YPD medium containing 
15% glycerol and stored a t  -80°C. 
TABLE 1 
Methanol Feed Profile during 60-L Fermentation 
Time, h Methanol feed rate, mL L-' h-' 
Fermentation. Frozen stock seed culture of P. pas- 
toris was grown at  30°C to an A,,, of five to six in shake 
flasks containing 200 ml of YNB plus phosphate me- 
dium (13.4 glL yeast nitrogen base without amino ac- 
ids, 20 glL glycerol, 0.4 mglL biotin, in 100 mM potas- 
sium phosphate buffer, pH 6.0). The shake flask 
culture was used to inoculate a 5-L BioFlo I11 seed 
fermentor (New Brunswick Scientific, Edison, NJ) con- 
taining 4% glycerol in 4 L basal-salt medium (BSM) 
(48) plus 2 mLlL of PTM, trace mineral salts. Dissolved 
oxygen (DO) was maintained a t  40%, and pH was con- 
trolled a t  5 using 30% ammonium hydroxide. The cul- 
ture was grown to an OD of 35 a t  600 nm. Large-scale 
fermentation was conducted with a starting volume of 
45 L of BSM plus 2 ml/L PTM, trace mineral salts, in 
a 60-L New Brunswick Scientific MPP-80 fermentor. 
The 60-L fermentor was inoculated with 3.5 L of the 
seed inoculum. The culture was grown to an OD of 57 
a t  600 nm, a t  which time the DO spiked indicating 
glycerol exhaustion. A 50% (wlv) glycerol solution was 
then fed into the fermentor a t  a rate of 20.2 ml L-' h-' 
for 60 min. The glycerol feed was then linearly reduced 
to zero over the next 3 h. After 1.5 h, when a glycerol 
feed rate of 10.0 ml L-' h-' was obtained, the methanol 
feed was started, beginning the induction phase. A 
solution of 100% methanol plus 1.2% PTM, was added 
a t  a rate of 5.0 ml L-' h-'. The methanol feed rate was 
increased over time to a final induction time of 9 h,  
according to the profile in Table 1. The final volume of 
the broth was 55 L with an OD of 165. Cells were 
harvested by centrifugation using a Westfalia SA-7 
disk stack centrifuge (Centrico, Inc., Northvale, NJ) 
and then stored frozen a t  -40°C until use. 
Cell disruption. Frozen cells were suspended into 
cold (4°C) lysis buffer (50 mM Mops, 0.25% Chaps, 50 
mM NaC1, 5 mM EDTA, 2 mM PMSF, pH 7.5) a t  200 
glL and disrupted a t  20,000 psig with five passes 
through a Microfluidics M- 1 1OEH homogenizer (Mi- 
crofluidics, Corp., Newton, MA) equipped with a heat 
exchanger for cooling. The lysate was centrifuged 
(Beckman, Palo Alto, CA) a t  12,000g for 25 min to 
pellet cell debris. Lysate supernatants were diluted 
with cold lysis buffer (without PMSF) to a total protein 
concentration of approximately 5 mg/ml and then fil- 
tered through a 0.5-pm filter (Pall, Port Washington, 
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NY) in preparation for loading onto the SP-Sepharose 
column, the first chromatography step. For lab-scale 
evaluations, cells were broken with six 1-min cycles in 
a bead blender containing 75-80 g cells, 160 ml beads, 
and 175 ml of lysis buffer. Following centrifugation, 
the supernatant was diluted with lysis buffer to a 
protein concentration of approximately 5 mglml for 
loading. 
Purification of rBoNTA (H,) fragment. A 1 0.0 -cm 
inner diameter (i.d.) BPG chromatography column 
(Pharmacia Biotech, Uppsala, Sweden), containing 2.0 
L of SP-Sepharose Fast Flow cation-exchange resin 
(Pharmacia), was used in the first purification step. 
The separation was performed by first equilibrating 
the resin with 12 column vol (CV) of buffer (50 mM 
Mops, 50 mM NaC1, 0.25% Chaps, 5 mM EDTA, pH 
7.5) a t  500 cmlh. The column was loaded with 6.6 L of 
diluted cell lysate a t  5.9 mglml total protein concentra- 
tion, a t  100 cmlh. Protein load was 19.5 mglml-resin. 
The column and buffers were maintained a t  ambient 
temperature, and the sample was kept on ice during 
loading. The column was washed with 2.5 CV of equil- 
ibration buffer a t  100 cmlh, followed by 7.5 CV a t  500 
cmlh. Product was desorbed by step elution with 6 CV 
of 300 mM NaCl in equilibration buffer (without 
EDTA). The column was eluted with 1 M NaCl in 
buffer and then cleaned with a mixture of 1 M NaOH 
and 1 M NaC1. The fraction obtained from the SP 
column was diafiltered a t  4°C against 5 vol of 50 mM 
Mops, 0.25% Chaps, pH 7.5, using 20 f t 2  of 5,000 
MWCO PES sheet membrane in a Septaport module 
(NC SRT, Cary, NC) to decrease the sample conductiv- 
ity in preparation for the second step. 
The second chromatography step was negative puri- 
fication using Q-Sepharose Fast Flow anion-exchange 
resin (Pharmacia). A 10.0-cm i.d. BPG column contain- 
ing 1.4 L of resin was equilibrated with 10 CV of buffer 
(50 mM Mops, 0.25% Chaps, pH 7.5) a t  450 cmlh prior 
to loading the diafiltered SP  product pool. The column 
and buffers were maintained a t  ambient temperature, 
and the sample was kept on ice during loading. After 
loading was complete, the column was washed with 6 
CV of equilibration buffer. The flowthrough fraction 
containing the rBoNTA(H,) product was collected. 
Bound proteins were eluted with a step to 1 M NaCl in 
Mops buffer. The column was cleaned with a mixture of 
1 M NaOH and 1 M NaC1. The Q product fraction was 
adjusted to 50 mM NaCl in preparation for the third 
step. 
The third chromatography column was a 10.0-cm i.d. 
column containing 1 L of Poros HS-50 (PE Biosystems, 
Framingham, MA). The column was equilibrated a t  
750 cmlh with 50 mM Mops, 0.05% Chaps, 75 mM 
NaC1, pH 7.5 for 10 CV. The Q product was applied a t  
750 cmlh. The column and buffers were maintained a t  
ambient temperature, and the sample was kept on ice 
during loading. A step to 180 mM NaCl in buffer for 8 
CV eluted the product. The column was flushed with 1 
M NaCl and then cleaned with a mixture of 1 M NaOH 
and 1 M NaC1. 
In the final chromatography step, the HS product 
fraction was adjusted to 2.6 M NaCl and applied to a 
6.0-cm i.d. column containing 700 ml of Phenyl 650C 
hydrophobic interaction (HIC) resin (TosoHaas, Mont- 
gomeryville, PA). The column was preequilibrated with 
10 CV of high-ionic-strength buffer (2.6 M NaCl in 50 
mM sodium phosphate, pH 7.5) a t  500 crnlh. The col- 
umn and buffers were maintained a t  ambient temper- 
ature, and the sample was kept on ice during loading. 
After loading was complete, the column was washed 
with 10 CV of equilibration buffer, and then product 
was eluted with a step to 50 mM NaCl in phosphate 
buffer and held for 6 CV. The column was cleaned with 
a mixture of 250 mM NaOH and 250 mM NaC1. 
The HIC product fraction was diafiltered using a 
10,000 MWCO, 3-ft2 spiral-wound cartridge (Millipore, 
Bedford, MA) against 20 mM sodium phosphate buffer, 
pH 7.5, to remove residual salt. The product was con- 
centrated to a final concentration of 0.2 mglmL, ali- 
quotted, and frozen a t  -70°C for storage. 
Total protein analysis. Total protein concentration 
of samples was determined using the Bio-Rad protein 
assay, based on the method of Bradford (49) (Bio-Rad 
Laboratories, Hercules, CA), using bovine serum albu- 
min (Pierce Chemical Co., Rockford, IL) as the refer- 
ence standard. 
SDS-PAGE and Western blot analysis. Samples 
taken a t  various stages of purification were analyzed 
by SDS-PAGE using 4 -20% gradient acrylamide gels 
(Novex, San Diego, CA) based on the method described 
by Laemmli (50). Samples were mixed with SDS- 
PAGE sample buffer containing 0-mercaptoethanol as 
a reducing agent. Gels were stained with either Coo- 
massie brilliant blue (Sigma Chemical Co., St. Louis, 
MO) or silver (Pharmacia). For Western blot analysis, 
the gels were transferred to a PVDF membrane (Bio- 
Rad) a t  100 V for 1.25 h. Blots were incubated in 5% 
nonfat dry milk for 1 h a t  ambient temperature, 
washed with 0.05% Tween 20 in phosphate-buffered 
saline, and then treated with the primary antibody, a 
rabbit polyclonal anti-BoNTA(H,) in PBS containing 
5% goat serum for 1 h a t  ambient temperature. Blots 
were again washed and then incubated with goat anti- 
rabbit IgG conjugated to horseradish peroxidase (HRP) 
(Kirkegaard & Perry Laboratories, Inc. (KPL), Gaith- 
ersburg, MD) diluted 115000 in PBS containing 5% goat 
serum for 1 h. Immunoreactive proteins were visual- 
ized by metal-enhanced DAB substrate (Pierce). 
Enzyme-linked immunosorbent assay (ELISA). 
Samples taken a t  various stages of purification were 
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TABLE 2 
Storage Time and  Cell Breakage of Pichia pastoris Cells, Lot No. AR-FPP-003-G 
Cell Age Percentage of disruption Lysate TP 
TP Concn released 
Run name Weeks Months Pass 1 Pass 2 Pass 3 Pass 4 Pass 5 (mglml) (mglg cells) 
003G 2 0.5 n.d." n.d. 87% n.d. 94% 14.2 90 
PPP-003 17 4.0 44% 74% 83% 85% 91% 12.9 86 
SP-Q 19 4.4 n.d. n.d. n.d. 90% 96% 8.8 7 5 
PPP-004 30 7.0 n.d. n.d. 67% 84% n.d. 8.7 6 2 
PPP-004.1 30 7.0 42% 51% 58% 72% 81% 7.8 60 
PPP-005 34 7.9 41% 54% 56% 66% 66% 5.9 5 0 
" n.d., not determined. 
analyzed by a sandwich ELISA. Ninety-six-well micro- 
titer plates were coated with a mouse anti-BoNTA(H,) 
monoclonal capture antibody (0.5 pgiml) a t  4°C over- 
night. Plates were washed with carbonate buffer (100 
mM sodium carbonatelbicarbonate, pH 9.6) plus 0.05% 
(wlv) Tween 20 and then blocked with 5% nonfat dry 
milk in carbonate buffer for 2- 4 h a t  37°C. Plates were 
again washed. Samples were diluted with 5% nonfat 
dry milk plus 0.05% Chaps in carbonate buffer and 
then added to wells and incubated a t  37°C for 
1.5 h. Plates were washed, and 2 pgiml horse anti- 
BoNTA(H,) polyclonal antibody was added to wells 
and incubated a t  37°C for 1 h. Plates were washed with 
phosphate-buffered saline plus 0.05% Tween 20 and 
0.01% thimerosal (PBS-TT). Plates were then incu- 
bated with 1 pgiml goat anti-horse IgG(H+L) horse- 
radish peroxidase-labeled antibody (KPL) a t  37°C for 
1 h. Plates were washed with the PBS-TT solution and 
incubated with ABTS peroxidase substrate solution 
(KPL) a t  37°C until darkest standard was a t  2 AU. A 
2% oxalic acid solution was added to stop color devel- 
opment, and color was measured using the MRX plate 
reader with Revelation software (Dynex Technologies, 
Inc., Chantilly, VA). Samples were quantified against a 
standard curve prepared from purified rBoNTA(H,) 
fragment. 
Dose response. Ten mice per group were vaccinated 
with purified rBoNTA(H,). Seven groups were injected 
with 11 ng per mouse, 33 ng per mouse, 100 ng per 
mouse, 300 ng per mouse, 900 ng per mouse, 2.7 pg per 
mouse, or 8.1 pg per mouse. The control group of ani- 
mals received diluent only (0.2% Alhydrogel in 0.8% 
saline with 0.8% benzyl alcohol as a preservative). 
Vaccines were administered intramuscularly in the 
hind leg muscle in a volume of 100 p1. Animals were 
challenged a t  2 1 days postvaccination with lo3 mouse 
LD5,/ml botulinum type A toxin diluted in gel-phos- 
phate buffer (0.4% dibasic phosphate with 0.2% gela- 
tin), delivered intraperitoneally. Mice were observed 
daily for 5 days postchallenge. 
Amino-terminal sequence analysis. The amino-ter- 
minal sequence of recombinant rBoNTA(H,) fragment 
was determined by automated Edman degradation 
performed on a Procise Model 49 1-HT amino acid se- 
quencer (PE Biosystems). 
RESULTS AND DISCUSSION 
Pilot-scale fermentation and purification processes 
and supporting lab-scale development work are pre- 
sented for isolating rBoNTA(H,) from P. pastoris. Dur- 
ing fermentation, the rBoNTA(H,) content in cells in- 
creases with induction time, until a plateau is reached, 
after which the rBoNTA(H,) concentration decreases 
quickly (47). The ratio of intracellular expressed 
rBoNTA(H,) to total protein drops after 10 -1 2 h of meth- 
anol induction, resulting in a shorter induction phase 
than is typical for expression in Pichia. Cells were 
harvested from the fermentor after 9 h of methanol 
feeding to maximize yield of the rBoNTA(H,) product. 
Expression of rBoNTA(H,) in Pichia was successful in 
both 5- and 60-L fermentations, and whole cells were 
stored a t  -30°C from time of harvest until use. A 20% 
suspension of frozen cells stored less than 6 months 
and disrupted a t  20,000 psig resulted in 90-95% cell 
breakage based on microscopic inspection. Cell lysis 
typically yielded a t  least 70 mg total protein (TP) per 
gram of wet cell weight after short-term storage. Sev- 
eral runs (lab and pilot scale) were performed using the 
same lot of cells over an 8-month period. Analysis of 
cell lysate protein concentration and percentage of 
breakage of cells revealed that long-term storage of 
cells severely affects protein yield and lysis efficiency 
(Table 2). This is likely due to dehydration of cells and 
resultant precipitation of protein during frozen stor- 
age. Ideally, the cells should be processed immediately 
for highest rBoNTA(H,) yield, but at maximum, frozen 
cells should be processed within 3 to 4 months of harvest. 
Purification of rBoNTA (Hc) fragment. The purifi- 
cation scheme described herein has repeatedly pro- 
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duced product of 95% purity based on silver-stained 
SDS-PAGE and 98% purity based on Coomassie- 
stained SDS-PAGE, with final product yields ranging 
from 100 to 450 mglkg of wet cell mass based on Brad- 
ford protein assay. Product stability increased with 
subsequent processing steps and cold storage of the 
Poros HS fraction pool (post-third step) proved accept- 
able for short periods. Expedient processing of the an- 
tigen after cell lysis was found imperative to product 
integrity. Initially, there was significant loss of product 
to the pellet upon centrifugation, the flowthrough frac- 
tion of the S column, and the bound fraction on the Q 
column. These observations were opposite to the ex- 
pected chromatographic behavior of the protein based 
on its basic isoelectric point (PI 9.3). Product loss was 
ascribed to suspected protein-protein andlor protein- 
DNA interactions occurring between the positively 
charged rBoNTA(H,) fragment and negatively charged 
cell components; therefore, zwittergent 3-10 and 3-12 
detergents (Calbiochem, La Jolla, CA) and the zwitte- 
rionic detergent Chaps (Calbiochem) were tested for 
their ability to break up these interactions. All were 
successful in combating the unwanted interactions. Of 
the three, Chaps was reported to be less denaturing to 
protein, so it was selected as a buffer additive. 
During initial screening, several resins of SP func- 
tionality were tested, including Streamline (Pharma- 
cia) expanded bed absorption chromatography (EBA). 
EBA however was not selected as a capture step for 
this protein because much of the product was lost to 
the flowthrough under the conditions tested (pH 
screening from 5 to 7 using various buffers and NaCl 
concentrations). Therefore, conventional chromatogra- 
phy was employed for capture. Initially, Poros HS resin 
(PE Biosystems) was used in the first step and the 
rBoNTA(H,) product was eluted with a gradient. This 
resulted in an elution profile of two fused peaks. The 
two peaks were fractionated and processed separately 
and determined there was no difference in the final 
product recovered from each peak. Product was present 
in both of the peaks, and resolution of these two peaks 
was not deemed necessary since contaminants were 
removed downstream. To decrease cost, the process 
was changed to use SP-Sepharose resin (Pharmacia) 
with step elution of the product. The SP-Sepharose 
resin also removed a contaminating 50-kDa band, non- 
reactive in Western blots. 
Loading study. A loading study based on total pro- 
tein loaded per milliliter of resin was performed using 
SP-Sepharose FF resin. The SP-Sepharose resin was 
evaluated for protein load capacity, as determined 
by breakthrough of rBoNTA(H,) product in the 
flowthrough (FT) fraction. A total of 50 mglml-resin 
was loaded onto a 108-ml column (2.7 X 19 cm) at 100 
c d h  and fractions were collected, each of which repre- 
I 
FIG. 1. Coomassie-stained SDS-PAGE gel of the process fractions. 
Lane 1, SP product; lane 2, Q product; lane 3, HS product; lane 4,  
final product; lane 5, MW standards, from bottom, 6, 16, 30, 36, 50, 
64, 98, and 250 kDa. Lane W, a Western blot of the product fraction 
probed with polyclonal rabbit anti-rBoNTA(H,) antibody and de- 
tected by HRP-DAB. 
sented approximately 2.5 mglml-resin loaded. The run- 
ning buffer was 50 mM Mops, 50 mM NaC1, 0.25% 
Chaps, pH 7.5, and column was eluted with a linear 
gradient to 250 mM. Product that eluted from the SP 
column was further processed using Q, HS, and HIC 
resins; final yield was 29.1 mg TP (375 mglkg cells). 
The cutoff for minimal loss of product to FT was 20 
mglml-resin; however, at  50 mglml-resin loss was less 
than 10%. A positive Western signal was detected in all 
flowthrough fractions, and immunoreactive bands at  
50, 36, and 17 kDa were detected, indicating degrada- 
tion. Under these conditions, 4% of the total protein 
loaded was recovered in the elution peak, and the prod- 
uct pool was approximately 25% rBoNTA(H,) fragment 
based on SDS-PAGE. 
SP cation-exchange chromatography efficiently cap- 
tured the rBoNTA(H,) fragment and with a large pro- 
portion of contaminating proteins flowing through the 
column. Based on an evaluation of flow velocity and 
protein concentration of the load material, maximum 
capture of product was achieved when total protein 
concentration was less than 5 mglml and load velocity 
was relatively slow at 100 c d h .  At pilot scale, the 
rBoNTA(H,) fragment was detected in the flowthrough 
fraction at less than 5% of the load based on ELISA. 
The SP product fraction contained approximately 25% 
Hc fragment based on ELISA and SDS-PAGE (Fig. 1, 
lane 1). 
The second chromatography step was a negative pu- 
rification step using Q-Sepharose FF (Pharmacia). The 
rBoNTA(H,) fragment is a basic protein with a p I  of 
9.3 and is present in the column flowthrough. This step 
removed many contaminants, some possibly associated 
with the product (Fig. 1, lane 2). Bound contaminants 
were eluted from the Q resin with 1 M NaCl for anal- 
ysis. A small portion of product was present in the Q 
elution fraction, determined less than 5%. 
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The third chromatography step utilized a Poros HS 
column, which removes a prominent higher molecular 
weight band from the product, as well as other less 
discernible bands. Analysis of the HS fractions by 
SDS-PAGE showed approximately 90% purity after 
this step. The product band (50 kDa) which is immu- 
noreactive by Western blot coelutes with a 17-kDa 
protein (Fig. 1, lane 3). 
Addition of Chaps to buffers. Due to high losses of 
product to the flowthrough fraction during initial cap- 
ture from lysate supernatants, it was speculated 
that  there was an interaction occurring between the 
rBoNTA(H,) and other proteins or nucleic acid. As 
mentioned previously, zwitterionic detergents were 
tested for their effect, and Chaps proved both to be 
nondenaturing and to have prevented product loss. 
Thus, Chaps facilitated the increased release of prod- 
uct from the cells and complete capture by the cation- 
exchange resin. Optimization of the capture step was 
performed using 0.05% Chaps in lysis and running 
buffers and included evaluation of lysate protein con- 
centration and load velocity, both a t  10 mglml resin on 
a 1.6-ml Poros HS column. There was no difference 
when 1 or 5 mglml lysate protein concentration was 
loaded onto the column a t  10 mglml-resin, 400 crdh 
load velocity, when comparing loss to flowthrough on 
the HS column. Both resulted in 17-18% product loss 
based on ELISA. Load velocities of 100, 200, 300, and 
400 cmlh were tested and lower load velocities resulted 
in increased product yield. Therefore, a load velocity of 
100 cmlh was selected. 
Chaps concentration was varied in the lysis buffer to 
see if increasing the Chaps would facilitate release of 
higher rBoNTA(H,) levels from cells into the superna- 
tant  fraction. Cells were lysed a t  small scale (1 -ml bead 
beater samples) in Mops lysis buffer a t  0.05, 0.1, 0.2, 
and 0.3% Chaps and supernatants were analyzed by 
ELISA. Varying concentrations of Chaps were added to 
the lysis and running buffers. The effect of Chaps on 
product capture was evaluated using a 1.6-ml Poros HS 
column, loading a t  10 mglml-resin, and a load velocity 
of 100 cmlh. The flowthrough fractions were tested for 
rBoNTA(H,) by ELISA and final yield calculated based 
on total protein. Results are summarized in Table 3. 
To confirm that  the increase in percentage of 
rBoNTA(H,) released from cells was a real phenome- 
non and not due to enhanced antibody-antigen affinity 
(detected by ELISA) due to Chaps interference, two 
complete purification runs were done a t  lab scale start- 
ing with a 100-ml HS column to capture a t  10 mglml- 
resin, comparing 0.25% Chaps and 0.05% Chaps. Yield 
was almost doubled using the higher Chaps to break 
cells and capture rBoNTA(H,) from supernatant, con- 
firming that  increased Chaps concentrations did facil- 
itate release of more rBoNTA(H,) from cells during 
TABLE 3 
Effect of the Zwitterionic Detergent Chaps 
on Capture and Yield of rBoNTA(H,) 
rBoNTA(Hc) rBoNTA(Hc) 
Concentration to total protein in flowthrough Final yield 
of Chaps (%) ratioa (%) fraction (%) of rBoNTA(Hc) 
0.05 2.3 17 7 1 mglkg cells 
0.10 4.5 8 n.d.b 
0.20 4.9 2 n.d. 
0.25 n.d. n.d. 123 mglkg cells 
0.30 6.0 3 n.d. 
" Released in supernatant 
* n.d., not determined. 
lysis. Based on these results, 0.25% Chaps was se- 
lected. 
Poros HS-50 resin was compared to Pharmacia SP- 
Sepharose FF resin for the capture step using 100-ml 
columns, and Poros HQ-50 was compared to Q-Sepha- 
rose FF  for the second step (80-ml columns). Two runs 
were done, both using 0.25% Chaps throughout steps 1 
and 2 in the process and then using 0.05% Chaps for 
step 3 (Poros HS, 28 ml), followed by HIC (no Chaps) as 
step 4. The purpose of using 0.25% Chaps throughout 
step 2 was to see if it would decrease the amount of 
rBoNTA(H,) lost to the Q elution fraction. At pH 7.5 
rBoNTA(H,) would have an expected net positive 
charge based on its isoelectric point of 9.3, and should 
flow through the positively charged Q column. How- 
ever, probable interactions with negatively charged 
molecules (in the absence of Chaps) were causing Q 
"binding." The Pharmacia resins yielded 191 mglkg of 
rBoNTA(H,) versus 132 mglkg with the Poros resins, 
and final product was of comparable purity. Therefore, 
the Pharmacia resins were exchanged for Poros in the 
first two steps in the process. Poros HS resin was still 
used in the third step, to take advantage of different 
selectivity between the two cation-exchange resins. 
PI 7 contaminating protein. A contaminating band 
of approximately 17 kDa was detected in the product 
fraction by SDS-PAGE from the initial stages of pro- 
cessing and was present upon cell lysis. I t  was very 
difficult to separate P17 from the BoNT-A(H,) frag- 
ment, indicating that it had similar chromatographic 
properties. Running various NaCl gradients on HS 
chromatography resulted in elution of P17 in the front 
shoulder of the rBoNTA(H,) peak, but the two were not 
able to be resolved. 
Diafiltra tion through 30K membrane. rBoNTA(H,) 
product containing P17 was diafiltered using a 30,000 
MWCO filter to see if the P17 would pass through 
while retaining the rBoNTA(H,) product. Figure 2 
shows the results of permeate and retentate samples 
taken a t  various times during the diafiltration process. 
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Product - 
FIG. 2. Silver-stained SDS-PAGE gel where the HS product was diafiltered to test for removal of PI7 through a 30-kDa MWCO membrane. 
Lane 1, permeate a t  1 diafiltration volume (DV); lane 2, retentate a t  1 DV; lane 3, MW standards, from bottom, 4, 6, 16, 30, 36, 50, 64, 98, 
and 250 kDa; lane 4, permeate a t  2 DV; lane 5, retentate a t  2 DV; lane 6, permeate a t  3 DV; lane 7, retentate a t  3 DV; lane 8, permeate a t  
4 DV; lane 9,  retentate a t  4 DV. 
The P17 protein was not readily separated, though 
over time the intensity of the P 17 band decreases rel- 
ative to the product band. P 17 that might have passed 
through the membrane was not detectable by silver- 
stained SDS-PAGE. There is some, albeit minimal, 
loss of the product through the membrane as well. The 
disadvantage of polishing the product to purity by this 
method was that at  higher diafiltration volumes, pre- 
cipitation of the protein began to occur. Alternately, a 
fourth chromatography step (HIC) was implemented. 
Hydrophobic interaction chromatography. P hen yl 
HIC was used as a polishing step to separate the 17- 
kDa protein from the 50-kDa product (Fig. 1, lane 4). 
Ammonium sulfate and sodium sulfate were both 
tested and resulted in two resolved peaks at  pH 8.5, 
but due to the volatility of ammonium sulfate at  this 
pH, ammonium sulfate gradients were not reproduc- 
ible from run to run. A nonvolatile alternative, sodium 
sulfate, worked well at  the high pH; however, clumping 
and slow dissolution of the salt when mixing buffers 
was problematic, especially at  pilot scale. Sodium chlo- 
ride was therefore investigated and found to be better 
a t  binding the product while selectively excluding P 17. 
Sodium chloride concentrations between 1 and 3 M 
were tested in 0.2 M increments to find the optimum 
binding characteristics. At lower NaCl concentrations, 
some product was lost to the flowthrough, yet a t  higher 
concentrations P 17 also bound. Optimum concentra- 
tion was found to be between 2.3 and 2.7 M NaC1. By 
excluding P 17 in the flowthrough fraction, the product 
TABLE 4 
Pilot Run Purification Table, Lot PPP-005 
Protein Concn Volume Total protein rBoNTA(Hc) rBoNTA(Hc) Fold 
Purification step (mglml)" (ml) (mg) (mg) (%) C purification 
Lysate 5.87 6600 38742 37 1 0.96 1 
SP-Sepharose pool 0.294 8650 2543 588 2 3 24 
Diafiltered for Q 0.200 7650 1530 
Q-Sepharose pool 0.055 16800 924 319 35 37 
Poros HS pool 0.103 3675 379 90 94 
HIC phenyl pool 0.090 2350 212 
Final product pool 0.210 820 180 197 99 103 
" Based on Bradford protein assay, quantitated from a BSA standard curve. 
Mass balance values are affected by a n  approximate 30% error associated with the ELISA assay. 
' Based on ELISA and/or SDS-PAGE gel analysis. 
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could be eluted in a single step to phosphate. Using 
phosphate as the buffering agent, the eluted product 
needed only to be concentrated and filtered prior to 
vialing. 
A summary of the recovery process run at pilot scale 
is presented in Table 4 and Fig. 1. The final yield of 
pure rBoNTA(Hc) from 785 g of wet cell mass was 172 
mg (219 mglkg). The first SP step was efficient at  
capturing 95% of rBoNTA(Hc) fragment from cell ly- 
sates. As mentioned previously, long-term storage of 
frozen cells affects yield upon cell lysis. Hence, final 
rBoNTA(Hc) yield is subsequently affected, compared 
with a maximum yield of 450 mg of rBoNTA(Hc) per 
kilogram of wet cell weight (Bradford protein assay) 
when using fresh cells. 
Amino-terminal sequence analysis. Amino-termi- 
nal sequencing indicated that the N-terminus of 
the purified product was 65% intact H,N-MRLL- 
STFTEYIK (the expected N-terminal sequence of 
rBoNTA(Hc)) and 35% H,N-STFTEYIKNI, a species 
missing the first four amino acids. The N-terminal 
sequence of P17 taken off PVDF membrane was H,N- 
XVNXQTXKRKDF, which does not match any internal 
sequence of rBoNTA(Hc). A sequence match for P 17 
was not found in the database (GenBank) for any 
catalogued Pichia protein, though homology to a 
chymotrypsin-like protease of Streptomyces sp. was 
suggested. 
Final product stability. Several agents were tested 
as possible storage buffers, including citrate, ascor- 
bate, succinate, phosphate, and glycine. Product, when 
stored frozen inthesk buffers ranging in pH from 5 to 
10, did not display much banding difference on SDS- 
PAGE over time (Fig. 3). The purified protein remained 
stable when frozen a t  -20°C in sodium phosphate, pH 
7.5, buffer. After 4 months, there was no difference in 
the banding pattern of the product. Stability of the 
purified antigen did not appear to be significantly de- 
pendent upon storage buffer conditions. 
The mouse model. An in vivo potency assay was 
necessary to evaluate the effects of manufacture, for- 
FIG. 3. Coomassie-stained SDS-PAGE gel of purified rBoNTA(Hc) 
after 8 weeks of storage a t  -20°C in buffers ranging from pH 5 to 10. 
Lane 1, MW standards, from bottom, 4, 6,  16, 30, 36, 50, 64, 98, and 
250 kDa; lane 2, pH 5; lane 3, pH 6; lane 4, pH 7; lane 5, pH 8;  lane 
6, pH 9; lane 7, pH 10; lane 8, pH 7 plus NaC1; lane 9, pH 8 plus NaC1. 
TABLE 5 
rBoNTA(H,) Challenge Data: Survivors per 10 Mice 
Reference cGMP 
Immunization Lot 55-153-C Lot 022399 
dose (EDSo = 0.04961 (EDSo = 0.05272 
(pglmouse) pglmouse) pglmouse) 
8.1 10110 1011 0 
2.7 10110 1011 0 
0.90 10110 10110 
0.30 10110 811 0 
0.10 8/10 611 0 
0.033 2/10 411 0 
0.01 1 1/10 211 0 
mulation, storage, and stability of botulinum Hc frag- 
ments as vaccine candidates. Since the recombinant 
product has no catalytic activity, it was assayed by 
testing the ability of the protein to elicit protective 
antibodies in mice, and the efficacious dose was (ED,,) 
determined for each batch of rBoNTA(Hc) vaccine. The 
dose-response ED,, curve was reproducible and sensi- 
tive to slight changes in potency. Vaccination with one 
0.10-pg dose of rBoNTA(Hc) fragment afforded protec- 
tion from challenge in 60% of the mice (Table 5), 0.30 
pg protected 80% of the mice, and 0.90 pg protected 
100% of mice challenged. The nontoxic H, fragment 
elicits an immune response in mice sufficient to pro- 
vide protection when challenged with native toxin. 
CONCLUSION 
Developing a large-scale purification process for the 
rBoNTA(Hc) was somewhat problematic due to its ba- 
sic isoelectric point and propensity to interact with 
negatively charged cell constituents, but incorporating 
Chaps into the lysis and running buffers alleviated this 
problem. Using aged cells in later pilot runs resulted in 
low yield compared to working with fresh cells on lab 
scale. Information regarding process validation was 
gained from this project, such as  limits on storage of 
cells and protein stability issues. Despite the laborious 
purification process, th; final pure ~BONTA(H,) prod- 
uct is stable, elicits protection in mice against native 
botulinum type A toxin, and is a good candidate for 
inclusion in a multivalent recombinant subunit vac- 
cine. 
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